MedPath

Fulvestrant

Generic Name
Fulvestrant
Brand Names
Faslodex, Fulvestrant Mylan
Drug Type
Small Molecule
Chemical Formula
C32H47F5O3S
CAS Number
129453-61-8
Unique Ingredient Identifier
22X328QOC4
Background

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

Indication

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Clinical Trials
Related News

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Phase 1
Recruiting
Conditions
Recurrent Breast Cancer
Metastatic Breast Cancer
Advanced Malignancies
Interventions
Drug: TQB2930 for injection
Drug: TQB3616 capsule
First Posted Date
2024-01-11
Last Posted Date
2024-03-12
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
154
Registration Number
NCT06202261
Locations
🇨🇳

Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China

🇨🇳

Affiliated cancer hospital of harbin medical university, Harbin, Heilongjiang, China

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2
Recruiting
Conditions
Locally Advanced Unresectable HER2-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Diagnostic Imaging
Other: Fludeoxyglucose F-18
Biological: Gonadotropin-releasing Hormone Analog
Procedure: Positron Emission Tomography
Drug: Therapeutic Estradiol
First Posted Date
2023-12-21
Last Posted Date
2025-03-12
Lead Sponsor
University of Washington
Target Recruit Count
60
Registration Number
NCT06179303
Locations
🇺🇸

Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Phase 1
Recruiting
Conditions
HR Positive/HER-2 Negative Breast Cancer
Interventions
First Posted Date
2023-12-15
Last Posted Date
2024-04-23
Lead Sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Target Recruit Count
42
Registration Number
NCT06172322
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Hormone Receptor Positive Malignant Neoplasm of Breast
Advanced Breast Cancer
Metastatic Breast Cancer
Hormone-receptor-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive HER-2 Negative Breast Cancer
Non-small Cell Lung Cancer
Hormone Receptor Positive Breast Carcinoma
Interventions
First Posted Date
2023-11-07
Last Posted Date
2025-05-09
Lead Sponsor
BeiGene
Target Recruit Count
79
Registration Number
NCT06120283
Locations
🇧🇷

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Brazil

🇧🇷

Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil

🇺🇸

Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States

and more 124 locations

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
Drug: Pembrolizuma
First Posted Date
2023-11-01
Last Posted Date
2025-04-06
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
43
Registration Number
NCT06110793
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2
Active, not recruiting
Conditions
Advanced or Metastatic Breast Cancer
Interventions
Drug: PF-07220060 CDK4 inhibitor
First Posted Date
2023-10-27
Last Posted Date
2025-03-18
Lead Sponsor
Pfizer
Target Recruit Count
333
Registration Number
NCT06105632
Locations
🇦🇷

Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina

🇦🇷

COE (Centro Oncológico de Excelencia), San Juan, Argentina

🇦🇷

Sanatorio Norte, Santiago del Estero, Argentina

and more 218 locations

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

Phase 1
Completed
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2023-10-10
Last Posted Date
2023-10-10
Lead Sponsor
Kashiv BioSciences, LLC
Target Recruit Count
48
Registration Number
NCT06074757
Locations
🇯🇴

Triumpharma Cro, Amman, Jordan

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3
Recruiting
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Drug: LHRH Agonist
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
First Posted Date
2023-10-04
Last Posted Date
2025-05-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1050
Registration Number
NCT06065748
Locations
🇨🇱

Clínica Puerto Montt, Puerto Montt, Chile

🇵🇪

Oncosalud Sac, Lima, Peru

🇩🇪

St. Elisabeth Krankenhaus Köln GmbH, Koeln, Germany

and more 319 locations

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

Phase 1
Active, not recruiting
Conditions
Advanced Breast Cancer
Interventions
Drug: BEBT-209 capsules
First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
BeBetter Med Inc
Target Recruit Count
106
Registration Number
NCT06047184
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Phase 3
Active, not recruiting
Conditions
Metastatic Breast Cancer
HER2 Negative Breast Carcinoma
Breast Cancer
Advanced Breast Cancer
ER Positive Breast Cancer
Interventions
First Posted Date
2023-08-30
Last Posted Date
2025-03-11
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
510
Registration Number
NCT06016738
Locations
🇬🇧

Clinical Trial Site, London, United Kingdom

🇲🇾

Clinical Trials Site, Sungai Petani, Kedah, Malaysia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy